RxSight Q3 Revenue Falls 19% to $24.6M; Net Loss Widens to $16.2M
RXST is trading near its 52-week low of $4.4 (4.3% above the low).
Summary
RxSight posted Q3 revenue of $24.6 million, down 19%, a wider net loss of $16.2 million, and gross margin of 73.6%, while holding $254.7 million in cash and investments.
Key Events · Earnings and Guidance · RXST
-
Q3 Revenue Down 19% to $24.6M
Total revenue of $24.6 million versus $30.3 million a year ago, driven by 23,128 LAL units and ongoing competitive pressures; Alcon collaboration revenue was minimal at $40 thousand.
-
Net Loss Widens to $16.2M
Net loss of $(16.2) million, or $(0.39) per share, versus $(9.8) million, or $(0.24) per share in Q3 2025; adjusted net loss was $(8.6) million, or $(0.21) per share.
-
Gross Margin Slips to 73.6%
Down from 79.9% a year ago on higher inventory reserves and higher LAL and LDD inventory costs, partly offset by favorable product mix.
-
$254.7M Cash After Alcon Payment
Cash, cash equivalents and short-term investments totaled $254.7 million at September 30, 2026, including the $60 million received in the quarter from the Alcon collaboration.
Analysis · RXST · Industrial Applications And Services
Revenue fell 19% year over year to $24.6 million as competitive pressure kept eroding LAL/LDD demand, and gross margin dropped to 73.6% from 79.9% on inventory reserves and higher lens and device costs. The net loss widened to $16.2 million from $9.8 million, so the restructuring and near-doubling of the sales force have not yet shown up in the numbers. The offset is liquidity: $254.7 million of cash and investments, including $60 million from Alcon, funds the turnaround push, but a new $50.0 million refund liability on the balance sheet is a claim on that cash that needs explaining. With the stock near its 52-week low, this print keeps the burden of proof on management's commercial rebuild.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RXST was trading at $4.59 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $190.9M. The 52-week trading range was $4.40 to $13.22. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.